ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

By Insights from 2023 ASCO® Annual Meeting FEATURING Vivek Subbiah

0 views

July 6, 2023

Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘ discusses the research conducted at The University of Texas MD Anderson Cancer Center, Houston, TX.
↖ read less

Comments 0

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

cfDNA for Liquid Biopsy for Patients With Glioblastoma

Feat. S. Bagley